197 related articles for article (PubMed ID: 30614530)
1. Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance.
Xu F; Sun Y; Yang SZ; Zhou T; Jhala N; McDonald J; Chen Y
Int J Cancer; 2019 Jul; 145(2):474-483. PubMed ID: 30614530
[TBL] [Abstract][Full Text] [Related]
2. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.
Yuan K; Sun Y; Zhou T; McDonald J; Chen Y
Clin Cancer Res; 2013 Sep; 19(17):4750-9. PubMed ID: 23833311
[TBL] [Abstract][Full Text] [Related]
3. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
Karpel-Massler G; Pareja F; Aimé P; Shu C; Chau L; Westhoff MA; Halatsch ME; Crary JF; Canoll P; Siegelin MD
PLoS One; 2014; 9(12):e114583. PubMed ID: 25531448
[TBL] [Abstract][Full Text] [Related]
5. The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand.
Yang SZ; Xu F; Zhou T; Zhao X; McDonald JM; Chen Y
J Biol Chem; 2017 Jun; 292(25):10390-10397. PubMed ID: 28476883
[TBL] [Abstract][Full Text] [Related]
6. Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.
Chen Z; Sangwan V; Banerjee S; Chugh R; Dudeja V; Vickers SM; Saluja AK
Cancer Lett; 2014 Jun; 348(1-2):156-66. PubMed ID: 24662747
[TBL] [Abstract][Full Text] [Related]
7. Regulation of pancreatic cancer TRAIL resistance by protein O-GlcNAcylation.
Yang SZ; Xu F; Yuan K; Sun Y; Zhou T; Zhao X; McDonald JM; Chen Y
Lab Invest; 2020 May; 100(5):777-785. PubMed ID: 31896813
[TBL] [Abstract][Full Text] [Related]
8. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
9. The herbal compound cryptotanshinone restores sensitivity in cancer cells that are resistant to the tumor necrosis factor-related apoptosis-inducing ligand.
Tse AK; Chow KY; Cao HH; Cheng CY; Kwan HY; Yu H; Zhu GY; Wu YC; Fong WF; Yu ZL
J Biol Chem; 2013 Oct; 288(41):29923-33. PubMed ID: 23986445
[TBL] [Abstract][Full Text] [Related]
10. Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.
Arafat W; Zhou T; Naoum GE; Buchsbaum DJ
J Egypt Natl Canc Inst; 2015 Dec; 27(4):205-15. PubMed ID: 26385392
[TBL] [Abstract][Full Text] [Related]
11. Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells.
Fancy RM; Kim H; Napier T; Buchsbaum DJ; Zinn KR; Song Y
J Cell Biochem; 2018 Jul; 119(7):6216-6230. PubMed ID: 29663486
[TBL] [Abstract][Full Text] [Related]
12. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
13. Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer.
Martínez-Bosch N; Iglesias M; Munné-Collado J; Martínez-Cáceres C; Moreno M; Guerra C; Yélamos J; Navarro P
J Pathol; 2014 Oct; 234(2):214-27. PubMed ID: 24889936
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome.
Tapodi A; Bognar Z; Szabo C; Gallyas F; Sumegi B; Hocsak E
Biochem Pharmacol; 2019 Apr; 162():98-108. PubMed ID: 30296409
[TBL] [Abstract][Full Text] [Related]
15. Seleno-cyclodextrin sensitises human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression.
Lin T; Ding Z; Li N; Xu J; Luo G; Liu J; Shen J
Eur J Cancer; 2011 Aug; 47(12):1890-907. PubMed ID: 21565489
[TBL] [Abstract][Full Text] [Related]
16. Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells.
Tanaka R; Tomosugi M; Horinaka M; Sowa Y; Sakai T
PLoS One; 2015; 10(5):e0125779. PubMed ID: 25955843
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression.
Meng XW; Koh BD; Zhang JS; Flatten KS; Schneider PA; Billadeau DD; Hess AD; Smith BD; Karp JE; Kaufmann SH
J Biol Chem; 2014 Jul; 289(30):20543-58. PubMed ID: 24895135
[TBL] [Abstract][Full Text] [Related]
18. Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
Quinonero F; Cepero A; Urbano D; Munoz-Gamez JA; Martin-Guerrero SM; Martin-Oliva D; Prados J; Melguizo C; Ortiz R
J Biosci; 2021; 46():. PubMed ID: 33576344
[TBL] [Abstract][Full Text] [Related]
19. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
20. Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody.
Huang ZQ; Buchsbaum DJ; Raisch KP; Bonner JA; Bland KI; Vickers SM
J Surg Res; 2003 May; 111(2):274-83. PubMed ID: 12850474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]